drugset / Trial / NCT01289990

Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes

NCT01289990

Phase 3 Completed 2705 enrolled Boehringer Ingelheim Eli Lilly and Company · collab
Non-randomizedParallel-groupDouble-blindTreatment

Summary

This study will investigate the efficacy and long term safety and tolerability of BI 10773 in type 2 diabetic patients.

Timeline

Start
2011-02
Primary completion
2013-05
Completion
2013-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 10 mg
Subject Empagliflozin Small molecule 25 mg
Comparator Sitagliptin Small molecule 100 mg